1. Is Venus Remedies Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Venus Remedies Ltd is a average quality company.
2. Is Venus Remedies Ltd undervalued or overvalued?
The key valuation ratios of Venus Remedies Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Venus Remedies Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Venus Remedies Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||12.7%||12.1%||4.4%||3.7%||0.9%||-0.9%||-1.1%||0.6%||10%||7.8%||-|
|Value Creation Index ⓘ||-0.1||-0.1||-0.7||-0.7||-0.9||-1.1||-1.1||-1.0||-0.3||-0.4||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||15.6%||-14.3%||-9.9%||-4.4%||-6.9%||-13.6%||5.4%||61.5%||9.2%||-|
|Adj EPS ⓘ||54.3||56.2||4.4||1.5||-15||-24.9||-20.1||-4.6||33.1||27.1||13.5|
|YoY Gr. Rt. %||-||3.4%||-92.1%||-66.9%||-1121.8%||NA||NA||NA||NA||-18%||-|
|BVPS (₹) ⓘ||355.1||403.4||399.1||382.5||314.9||293.2||269.4||262||313.2||329.5||337.3|
|Adj Net Profit ⓘ||57.3||64.3||5.1||1.7||-18.5||-30.8||-24.8||-5.7||40.8||36.2||18|
|Cash Flow from Ops. ⓘ||52.2||52.7||67.8||46.9||58.9||31.2||45.3||77.6||132||41||-|
|Debt/CF from Ops. ⓘ||5.2||5.5||4.7||7.2||5.3||9.8||6.6||2.8||0.4||1||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||-7.4%||NA||NA||-18%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||16.7||15.3||1.1||0.4||-4.5||-8.2||-7.1||-1.7||11.3||8.6||4.1|
|Op. Profit Mgn % ⓘ||25.6||25.5||19.2||19.4||12.7||10.6||10.1||12||9.8||10.4||8.3|
|Net Profit Mgn % ⓘ||12.2||11.9||1.1||0.4||-4.6||-8.3||-7.7||-1.7||7.5||6.1||3.3|
|Debt to Equity ⓘ||0.7||0.6||0.7||0.8||0.8||0.9||0.9||0.7||0.1||0.1||0.1|
|Working Cap Days ⓘ||177||197||251||270||270||285||337||338||188||152||190|
|Cash Conv. Cycle ⓘ||106||107||135||153||152||153||170||147||70||55||136|
Sales growth is growing at healthy rate in last 3 years 22.98%
Return on Equity has declined versus last 3 years average to 4.10%
Net Profit has been subdued in last 3 years 0.00%
Sales growth is not so good in last 4 quarters at 2.18%
|TTM EPS (₹)||21.8||13.5|
|TTM Sales (₹ Cr.)||525||549|
|BVPS (₹.) ⓘ||350.4||337.3|
|Reserves (₹ Cr.) ⓘ||455||437|
|From the Market|
|52 Week Low / High (₹)||178.65 / 531.00|
|All Time Low / High (₹)||1.00 / 638.50|
|Market Cap (₹ Cr.)||266|
|Equity (₹ Cr.)||13.4|
|Face Value (₹)||10|
|Industry PE ⓘ||37.8|
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.
Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.
Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.
Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.
Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.
Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.
The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNILâ€ in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.